Literature DB >> 15224400

Ultrastructural evidence for co-localization of dopamine D2 and micro-opioid receptors in the rat dorsolateral striatum.

L M Ambrose1, E M Unterwald, E J Van Bockstaele.   

Abstract

Previous studies have shown significant changes in dopamine and opioid receptors in the basal ganglia following administration of cocaine. Cocaine administration results in a significant increase in the number of opioid receptors in dopamine-enriched brain regions. The aim of this study was to determine if dopamine D2 receptors (D2r) and micro-opioid receptors (microOr) are localized to the same neurons in the dorsolateral striatum. Immunoperoxidase and immunogold-silver labeling combined with electron microscopy was used to examine the ultrastructural localization of both receptors in the dorsolateral striatum. Approximately half of the microOr-labeled somatodendritic processes showed immunolabeling for the D2r. Similarly, about half of the D2r-labeled dendrites and cell bodies showed immunolabeling for the microOr. In conclusion, our results indicate that individual neurons in the rat dorsolateral striatum may be directly modulated by both dopaminergic and opioid ligands. These data also suggest that the molecular mechanism responsible for the up-regulation of microOrs in the caudate and putamen following cocaine exposure may depend, in part, on the co-existence of D2rs and micro-Ors in these cells. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15224400     DOI: 10.1002/ar.a.20054

Source DB:  PubMed          Journal:  Anat Rec A Discov Mol Cell Evol Biol        ISSN: 1552-4884


  20 in total

1.  Oxycodone lengthens reproductions of suprasecond time intervals in human research volunteers.

Authors:  Cynthia M Gooch; Brian C Rakitin; Ziva D Cooper; Sandra D Comer; Peter D Balsam
Journal:  Behav Pharmacol       Date:  2011-08       Impact factor: 2.293

Review 2.  The opioid receptors as targets for drug abuse medication.

Authors:  Florence Noble; Magalie Lenoir; Nicolas Marie
Journal:  Br J Pharmacol       Date:  2015-06-26       Impact factor: 8.739

Review 3.  The endogenous opioid system in cocaine addiction: what lessons have opioid peptide and receptor knockout mice taught us?

Authors:  Ji Hoon Yoo; Ian Kitchen; Alexis Bailey
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 4.  Neural vulnerability factors for obesity.

Authors:  Eric Stice; Kyle Burger
Journal:  Clin Psychol Rev       Date:  2018-12-19

5.  Mu-opioid receptors modulate the stability of dendritic spines.

Authors:  Dezhi Liao; Hang Lin; Ping Yee Law; Horace H Loh
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-19       Impact factor: 11.205

6.  Treatment-like steady-state methadone in rats interferes with incubation of cocaine sensitization and associated alterations in gene expression.

Authors:  Francesco Leri; Yan Zhou; Brendan Carmichael; Erin Cummins; Mary Jeanne Kreek
Journal:  Eur Neuropsychopharmacol       Date:  2011-07-13       Impact factor: 4.600

7.  The differential contribution of dopamine D(1) and D (2) receptors to mu-opioidergic immunomodulation.

Authors:  M A Cheido; G V Idova
Journal:  Neurosci Behav Physiol       Date:  2007-09

8.  Steady-state methadone blocks cocaine seeking and cocaine-induced gene expression alterations in the rat brain.

Authors:  Francesco Leri; Yan Zhou; Benjamin Goddard; AnneMarie Levy; Derek Jacklin; Mary Jeanne Kreek
Journal:  Eur Neuropsychopharmacol       Date:  2008-11-06       Impact factor: 4.600

9.  Separate and combined impact of acute naltrexone and alprazolam on subjective and physiological effects of oral d-amphetamine in stimulant users.

Authors:  Katherine R Marks; Joshua A Lile; William W Stoops; Craig R Rush
Journal:  Psychopharmacology (Berl)       Date:  2014-01-25       Impact factor: 4.530

10.  Cocaine-induced mu opioid receptor occupancy within the striatum is mediated by dopamine D2 receptors.

Authors:  Avery R Soderman; Ellen M Unterwald
Journal:  Brain Res       Date:  2009-08-20       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.